Literature DB >> 8985517

Prognostic importance of histomorphologic subclassification for epithelial thymic tumors.

P M Schneider1, C Fellbaum, U Fink, E Bollschweiler, H W Präuer.   

Abstract

BACKGROUND: The prognostic importance of various clinical variables (age, sex, association with myasthenia gravis), staging according to Masaoka, histologic type according to the Marino/Kirchner/Müller-Hermelink (MKM-H) classification, and residual tumor category (R category) was evaluated in a retrospective analysis.
METHODS: Eighty-two patients with epithelial thymic tumors (ETTs) treated in the period 1969-1993 were evaluated, and archived specimens were histologically reclassified according to the classification of MKM-H.
RESULTS: Age, sex, and association with myasthenia gravis were of no prognostic importance. The R category is of significant prognostic importance, with 5- and 10-year survival rates of 93.6% and 87.3%, respectively, for R0 resections compared with 0% at 5 years for R1 and R2 resections (p < 0.001). Staging (Masaoka) proved to be a prognostic factor (5-/10-year survival: stage I, 100%/90.9%; II, 95%/88.2%; III, 55.9%/46.6%; and IV, 10.8%/ 10.8%; p < 0.001). Histologic typing according to MKM-H is also of significant prognostic importance (5/10 year survival: thymomas: medullary, 100%/100%; mixed, 100%/100%, predominantly cortical, 68.6%/68.6%; cortical, 65.8%/65.8%; thymic carcinomas: well-differentiated type, 62.3%/44.5%; thymic carcinomas other than well-differentiated type, 33.6%/26.9%; p < 0.001). Multivariate analysis demonstrated that staging (p < 0.001), R category (p < 0.026), and MKM-H classification (p < 0.028) have an independent impact on survival.
CONCLUSIONS: Staging (Masaoka), R category, and histologic classification (MKM-H) are important independent prognostic factors for patients with epithelial thymic tumors. Complete (R0) surgical resections should be the ultimate goal in the clinical management of patients with epithelial thymic tumors.

Entities:  

Mesh:

Year:  1997        PMID: 8985517     DOI: 10.1007/bf02316810

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  6 in total

1.  The World Health Organization (WHO) histologic classification of thymomas: a reanalysis.

Authors:  Cesar A Moran; Saul Suster
Journal:  Curr Treat Options Oncol       Date:  2009-02-04

2.  Clinical and pathologic predictors of survival in patients with thymoma.

Authors:  K B Wilkins; E Sheikh; R Green; M Patel; S George; M Takano; M Diener-West; J Welsh; S Howard; F Askin; G B Bulkley
Journal:  Ann Surg       Date:  1999-10       Impact factor: 12.969

3.  Radiotherapy for invasive thymoma and thymic carcinoma. Clinicopathological review.

Authors:  R Mayer; C Beham-Schmid; R Groell; F M Smolle-Juettner; F Quehenberger; G F Stuecklschweiger; U Prettenhofer; H Stranzl; H Renner; A Hackl
Journal:  Strahlenther Onkol       Date:  1999-06       Impact factor: 4.033

4.  Thymoma masquerading as transfusion dependent anemia.

Authors:  Javvid Muzamil; Aejaz Aziz Shiekh; Gull Mohammad Bhat; Abdul Rashid Lone; Shuaeb Bhat; Firdousa Nabi
Journal:  Indian J Med Paediatr Oncol       Date:  2016 Oct-Dec

5.  Impact of Definitive Radiotherapy and Surgical Debulking on Treatment Outcome and Prognosis for Locally Advanced Masaoka-Koga stage III Thymoma.

Authors:  Chengcheng Fan; Hong Ge; Shaokai Zhang; Wenqun Xing; Ke Ye; Yan Zheng; Haibo Sun; Hao Wang; Xiaoli Zheng; Ruiyun Zhang; Meiling Liu
Journal:  Sci Rep       Date:  2020-02-03       Impact factor: 4.379

Review 6.  The role of induction therapy for thymic malignancies: a narrative review.

Authors:  Deven C Patel; Joseph B Shrager; Sukhmani K Padda
Journal:  Mediastinum       Date:  2020-12-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.